KCTD16: A Potential Drug Target for Various Diseases (G57528)

Target Name: KCTD16

NCBI ID: G57528

KCTD16

KCTD16: A Potential Drug Target for Various Diseases

KCTD16 is a protein that is expressed in various tissues of the human body, including the brain, heart, and kidneys. It is a member of the Kallikrein-related peptidases (KLK) family 16, which are involved in the regulation of various cellular processes, including cell signaling, inflammation, and fibrosis. KCTD16 has been identified as a potential drug target due to its unique structure and the involvement of several diseases, including cancer, cardiovascular disease, and neurodegenerative disorders.

The KLK family is characterized by the presence of a catalytic center composed of a specific amino acid residue, known as KLK-36, which is responsible for the peptide bond formation. KCTD16 is unique in that it contains a different catalytic center, known as KLK-16, which is located at the N-terminus of the protein. This structural difference allows KCTD16 to have different cellular localization and functions than other KLK proteins.

KCTD16 has been shown to play a role in various physiological processes, including cell signaling, inflammation, and fibrosis. For example, KCTD16 has been shown to regulate the activity of several signaling pathways that are involved in cancer progression, including the TGF-β pathway, which is involved in the regulation of cell growth, angiogenesis, and survival. In addition, KCTD16 has been shown to play a role in the regulation of inflammation, including the production of pro-inflammatory cytokines.

KCTD16 has also been shown to be involved in the regulation of cellular processes that are relevant to various neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. These disorders are characterized by the accumulation of neurofibrillary tangles and the loss of dopamine-producing neurons in the brain, which can lead to the symptoms of cognitive impairment and motor dysfunction. KCTD16 has been shown to be involved in the regulation of the formation of these tangles and the disruption of the dopamine network, which are thought to contribute to the development of these disorders.

In addition to its involvement in cellular processes, KCTD16 has also been shown to be involved in the regulation of protein levels in the brain. This is important because changes in the levels of proteins in the brain can have a significant impact on cellular processes and the development of neurodegenerative disorders. For example, KCTD16 has been shown to play a role in the regulation of the levels of the protein tau, which is involved in the regulation of microtubules in the brain. The accumulation of tau in the brain is thought to contribute to the development of neurodegenerative disorders, including Alzheimer's disease.

Given its involvement in a wide range of physiological processes, KCTD16 is a promising target for drug development. Studies have shown that inhibition of KCTD16 can have a variety of therapeutic effects, including the inhibition of cancer cell growth, the regulation of inflammation, and the relief of neurodegenerative symptoms. In addition, KCTD16 has been shown to be involved in several diseases, including cancer, cardiovascular disease, and neurodegenerative disorders, which makes it an attractive target for the development of new treatments.

In conclusion, KCTD16 is a protein that has been identified as a potential drug target due to its unique structure and the involvement of several diseases. Its role in the regulation of cellular processes, including cell signaling, inflammation, and fibrosis, makes it an attractive target for the development of new treatments. Additionally, KCTD16 has been shown to play a role in the regulation of protein levels in the brain, which is important for the development

Protein Name: Potassium Channel Tetramerization Domain Containing 16

Functions: Auxiliary subunit of GABA-B receptors that determine the pharmacology and kinetics of the receptor response. Increases agonist potency and markedly alter the G-protein signaling of the receptors by accelerating onset and promoting desensitization (By similarity)

The "KCTD16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCTD16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets